FirasBenyamineBadinMD

Oncology • Lexington, KY

Physician

Join to view full profile

Dr. Badin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Badin's full profile

Already have an account?

Office
1700 Nicholasville Road
Suite 100
Lexington, KY 40503
Phone+1 859-276-0414

Fax+1 859-276-3765
Is this information wrong?

Education & Training

University of Kentucky College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
Rutgers Health/Newark Beth Israel Medical CenterResidency, Internal Medicine, 2005 - 2008
Damascus University Faculty of MedicineClass of 2004

Certifications & Licensure

KY State Medical License 2008 - 2025
NJ State Medical License 2006 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013-2014

Clinical Trials

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 01
Completed
Phase 3
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 16
Terminated
Phase 2
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 02
Completed
Phase 1, Phase 2
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Start of enrollment: 2020 May 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Firas Badin> ;Cancer Treatment and Research Communications. 2024 Feb 29
Breast cancer quality of care in Syria: screening, diagnosis, and staging.
Nahhat, F., Doyya, M., Zabad, K., Laban, T., Najjar, H., Saifo, M., Badin, F.> ;BMC Cancer. 2023 Dec 14
8 citations
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic lit...
Kenneth O'Byrne, Evan Popoff, Firas Badin, Adam Lee, Yong Yuan, Greta Lozano-Ortega, Laura J Eccles, Nebibe Varol, Nathalie Waser, John R Penrod, Sarah Goring> ;Lung Cancer. 2023 Mar 1
Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Connor Willis, Hillevi Bauer, Trang H Au, Jyothi Menon, Sudhir Unni, Dao Tran, Zachary Rivers, Wallace Akerley, Matthew B Schabath, Firas Badin, Ashley Sekhon, Malini ...> ;Oncotarget. 2022 Dec 6
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
Connor Willis, Hillevi Bauer, Trang H Au, Jyothi Menon, Sudhir Unni, Dao Tran, Zachary Rivers, Wallace Akerley, Matthew B Schabath, Firas Badin, Ashley Sekhon, Malini ...> ;Oncotarget. 2022 Jan 1
10 citations
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodriguez Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse A...> ;Clinical Lung Cancer. 2019 Jan 4
3 citations
Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness
Firas Benyamine Badin, John Hayslip> ;Clinicoeconomics and Outcomes Research. 2010 Apr 7
Join now to see all

Press Mentions

Dr. Moncef Slaoui: White House’s Arab American ‘Coronavirus Vaccine Czar’May 20th, 2020

Hospital Affiliations

Baptist Health LexingtonLexington, Kentucky
Baptist Health RichmondRichmond, Kentucky

FirasBenyamineBadinMD

Dr. Badin is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.